Non-Invasive Imaging of Phosphoinositide-3-Kinase-Catalytic-Subunit-Alpha (PIK3CA) Promoter Modulation in Small Animal Models

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Gaikwad, Snehal M ^a   Gunjal, Lata ^a   Junutula, Anitha R ^b   Astanehe, Arezoo ^c   Gambhir, Sanjiv Sam ^b   Ray, Pritha ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FIREFLY LUCIFERASE; FIREFLY LUCIFERASE 2; PACLITAXEL; PHOSPHOINOSITIDE 3 KINASE CATALYTIC SUBUNIT ALPHA; PROTEIN P53; RED FLUORESCENT PROTEIN; THYMIDINE KINASE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BINDING SITE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; FEMALE; GERM LINE; HUMAN; HUMAN CELL; MOLECULAR IMAGING; MOLECULAR LIBRARY; MOUSE; MULTIPLE CYCLE TREATMENT; NON INVASIVE PROCEDURE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BINDING SITES; BLOTTING, WESTERN; CELL LINE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; POSITRON-EMISSION TOMOGRAPHY; PROMOTER REGIONS, GENETIC;

EID: 84873518421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055971     Document Type: Article

References (36)

1. Bunney TD, Katan M, (2010) Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 10: 342-352.
2. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
3. Yuan TL, Cantley LC, (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
4. Bader AG, Kang S, Zhao L, Vogt PK, (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929.
5. Gaikwad SM, Ray P, (2012) Non-invasive Imaging of PI3K/Akt/mTOR signalling in Cancer. American Journal of Nuclear Medicine and Molecular Imaging. 2(4): 418-431.
6. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, et al. (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24: 1477-1480.
7. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, et al. (2009) PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 8: 21-26.
8. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
9. Network TCGA, (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
10. Abedini MR, Muller EJ, Bergeron R, Gray DA, Tsang BK (2009) Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene. 11-25.
11. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, et al. (2003) Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 1: 66.
12. Astanehe A, Arenillas D, Wasserman WW, Leung PC, Dunn SE, et al. (2008) Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 121: 664-674.
13. Yang N, Huang J, Greshock J, Liang S, Barchetti A, et al. (2008) Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS One 3: e1758.
14. Massoud TF, Gambhir SS, (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17: 545-580.
15. Min JJ, Ahn Y, Moon S, Kim YS, Park JE, et al. (2006) In vivo bioluminescence imaging of cord blood derived mesenchymal stem cell transplantation into rat myocardium. Ann Nucl Med 20: 165-170.
16. Ray P, Bauer E, Iyer M, Barrio JR, Satyamurthy N,et al. (2001) Monitoring gene therapy with reporter gene imaging. Semin Nucl Med 31: 312-320.
17. Doubrovin M, Serganova I, Mayer-Kuckuk P, Ponomarev V, Blasberg RG, (2004) Multimodality in vivo molecular-genetic imaging. Bioconjug Chem 15: 1376-1388.
18. Mayer-Kuckuk P, Menon LG, Blasberg RG, Bertino JR, Banerjee D, (2004) Role of reporter gene imaging in molecular and cellular biology. Biol Chem 385: 353-361.
19. Ray P, De A, Patel M, Gambhir SS, (2008) Monitoring caspase-3 activation with a multimodality imaging sensor in living subjects. Clin Cancer Res 14: 5801-5809.
20. Ray P, Tsien R, Gambhir SS, (2007) Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res 67: 3085-3093.
21. Ray P, Wu AM, Gambhir SS, (2003) Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res 63: 1160-1165.
22. Cao F, Lin S, Xie X, Ray P, Patel M, et al. (2006) In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 113: 1005-1014.
23. Shu CJ, Guo S, Kim YJ, Shelly SM, Nijagal A, et al. (2005) Visualization of a primary anti-tumor immune response by positron emission tomography. Witte ONProc Natl Acad Sci U S A 102(48): 17412-17417.
24. Yaghoubi SS, Creusot RJ, Ray P, Fathman CG, Gambhir SS, (2007) Multimodality imaging of T-cell hybridoma trafficking in collagen-induced arthritic mice: image-based estimation of the number of cells accumulating in mouse paws. J Biomed Opt 12: 064025.
25. Chudakov DM, Matz MV, Lukyanov S, Lukyanov KA, (2010) Fluorescent proteins and their applications in imaging living cells and tissues. Physiol Rev 90: 1103-1163.
26. DeBlasio SL, Sylvester AW, Jackson D, (2010) Illuminating plant biology: using fluorescent proteins for high-throughput analysis of protein localization and function in plants. Brief Funct Genomics 9: 129-138.
27. Lippincott-Schwartz J, Patterson GH, (2003) Development and use of fluorescent protein markers in living cells. Science 300: 87-91.
28. Ray P, De A, Min JJ, Tsien RY, Gambhir SS, (2004) Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res 64: 1323-1330.
29. Shaner NC, Lin MZ, McKeown MR, Steinbach PA, Hazelwood KL, et al. (2008) Improving the photostability of bright monomeric orange and red fluorescent proteins. Nat Methods 5: 545-551.
30. Siddik ZH, (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
31. Rakovitch E, Mellado W, Hall EJ, Pandita TK, Sawant S, et al. (1999) Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation. Int J Radiat Oncol Biol Phys 44: 1119-1124.
32. Prasad SB, Rosangkima G, Khyynriam D, (2006) Cisplatin-induced Toxicological Effects in Relation to the Endogenous Tissue Glutathione Level in Tumor-Bearing Mice. Asian J Exp Sci, Vol 20: 55-68.
33. Agarwal R, Kaye SB, (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516.
34. Massoud TF, Paulmurugan R, De A, Ray P, Gambhir SS, (2007) Reporter gene imaging of protein-protein interactions in living subjects. Curr Opin Biotechnol 18: 31-37.
35. Winnard PT Jr, Kluth JB, Raman V, (2006) Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer. Neoplasia 8: 796-806.
36. Giannakakou P, Robey R, Fojo T, Blagosklonny MV, (2001) Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20: 3806-3813.